Abbott

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Abbott sits in the top decile of US sponsors by registered trial count (#166 of 15,742 sponsors by registered trial count).

181 total trials none currently recruiting 158 completed top decile by trial count

Abbott: 181 sponsored US clinical trials, none currently recruiting.

Abbott sponsors 181 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 158 completed. 90 of these trials are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 7 trials.

Top-decile sponsor footprint

Abbott ranks in the top decile of sponsors by registered trial count (#166 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 58/100

158 of 181 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

181 total, page 2 of 4

COMPLETED Phase 1

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00666692

COMPLETED Phase 3

A Study of Leuprolide to Treat Prostate Cancer

NCT00626431

COMPLETED Phase 3

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158

COMPLETED Phase 3

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

NCT00630877

COMPLETED Phase 3

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

NCT00626392

COMPLETED Phase 3

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

NCT00566722

COMPLETED Phase 3

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

NCT00647270

TERMINATED Phase 2

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

NCT00555204

TERMINATED Phase 2

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

NCT00562887

TERMINATED Phase 2

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00554385

COMPLETED Phase 3

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

NCT00491530

COMPLETED Phase 3

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

NCT00409682

COMPLETED Phase 3

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

NCT00465088

TERMINATED Phase 1

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

NCT00354562

COMPLETED Phase 3

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

NCT00427921

COMPLETED Phase 2

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00429091

COMPLETED Phase 2

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

NCT00421733

COMPLETED Phase 4

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

NCT00420927

COMPLETED Phase 3

A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy

NCT00402792

TERMINATED Phase 2

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

NCT00412620

TERMINATED Phase 2

A Study of Volociximab in Metastatic Melanoma

NCT00369395

COMPLETED Phase 3

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT00408629

COMPLETED Phase 3

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

NCT00385736

COMPLETED Phase 2

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00391729

COMPLETED Phase 3

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

NCT00300430

COMPLETED Phase 3

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

NCT00358917

COMPLETED Phase 3

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

NCT00348283

COMPLETED Phase 4

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

NCT00257920

COMPLETED Phase 3

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650

COMPLETED Phase 3

A Study of Pain Relief in Low Back Pain

NCT00325949

TERMINATED Phase 2

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

NCT00307827

COMPLETED Phase 3

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300482

COMPLETED Phase 3

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300469

COMPLETED Phase 3

Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300456

COMPLETED Phase 3

A Study of Pain Relief in Osteoarthritis

NCT00298974

TERMINATED Phase 2

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

NCT00275262

COMPLETED Phase 3

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

NCT00262522

COMPLETED Phase 3

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

NCT00235885

COMPLETED Phase 3

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820

COMPLETED Phase 3

Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain

NCT00195728

TERMINATED Phase 4

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

NCT00233558

COMPLETED Phase 2

Endometriosis Trial: Study of NBI-56418 in Endometriosis

NCT00109512

COMPLETED Phase 3

A Study for Treatment of Partial Seizures in Children

NCT00102713

COMPLETED Phase 3

A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

NCT00195780

COMPLETED Phase 3

Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine

NCT00195806

COMPLETED Phase 3

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

NCT00234910

TERMINATED Phase 2

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

NCT00100685

COMPLETED Phase 3

Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00105300

COMPLETED Phase 3

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

NCT00195715

COMPLETED Phase 4

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

NCT00073710

← Previous Page 2 of 4 Next →

How the Abbott archive is shaped

181 indexed studies, none listed as recruiting (0% open); 158 completed (87%).

Phase mix: 90 late (III/IV) vs 83 early (I/II) (balanced across stages).

Top condition: Healthy (7 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Abbott: archived-pipeline peers nationwide

Peers matched on 181 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Abbott sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 0%5%10%15%20% Total trials Recruiting share AbbottViiV HealthcareBaylor Research InstituteFox Chase Cancer CenterChildren's Mercy Hospital Kansas City10xBio22nd Century Group23andMe3-C Institute for Social Development
Abbott sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Abbott sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 181 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Abbott page

181 registered trials is a research-attention snapshot, not an endorsement of Abbott or any single study.

  • None of Abbott's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Abbott studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Abbott pipeline card: 181 registered trials from official public datasets.Report a data error.